Here, we’ll walk through what has actually changed in the CBD market since 2021, and the four things worth checking before you buy your next CBD product.
Most of what you can read online about buying CBD was written between 2019 and 2021, when the category was pushing into every gas station, gym, and grocery aisle in the country. The advice from that era assumed CBD would simply keep spreading outward.
It has not worked out that way. Regulators have spent the past two years redrawing the line between hemp and cannabis, and a large slice of what used to sit beside the register has been reclassified and moved behind a licensed counter. Plain CBD is still widely available, but the market around it no longer matches the guides describing it.
Here is what changed, followed by four things worth checking before you spend anything.
What changed for anyone buying CBD
Hemp got redefined
The 0.3 percent THC threshold was always the dividing line, but products engineered around it, delta-8, delta-10, and THCA flower among them, sat in a gap the original rules never anticipated. States have been closing that gap one at a time. New Jersey, for instance, has made it unlawful to sell those products outside the licensed cannabis market, and other states have moved the same way.
The practical effect is that something you bought at a smoke shop in 2023 may now be legally classified as cannabis, available only through a licensed retailer, and subject to testing rules it previously escaped entirely.
Where those products went
Convenience stores, gas stations, and vape shops cleared the affected inventory off their shelves. Demand did not leave with it.
Licensed cannabis retailers absorbed most of it. Operators like Silverleaf were already required to keep batch-level test results, verify age at the door, and log every sale, so taking on reclassified products changed their paperwork rather than their process. The gap in accountability between the two channels was always there. It is just visible now.
Check the certificate of analysis
What the report confirms
A certificate of analysis, usually shortened to COA, comes from a laboratory with no financial stake in the product. It states how much CBD is actually in the bottle, how much THC came along with it, and whether the batch screened clean for pesticides, heavy metals, residual solvents, and microbial contamination. Accreditation to ISO 17025 is the credential worth looking for on the letterhead.
Match the batch number
This is the step most buyers skip. The batch or lot number on the report has to match the number printed on your package, because a COA for a different batch tells you nothing about the jar in your hand. Check the test date as well. A document from three years ago is not evidence about current stock. If a seller cannot produce a COA at all, you have your answer.
Check what the label is allowed to promise
One CBD product has federal approval
The Food and Drug Administration has approved a single CBD product, a prescription drug for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year and older. Everything else on the market sits outside that approval. The agency has also stated that adding CBD to food or marketing it as a dietary supplement is not currently legal, and that the limited safety data available point to real risks.
Cure language is a warning sign
So a package promising to treat, cure, or prevent a named condition is making a claim it has no standing to make, which tells you something useful about the operator behind it. A plain description of what a product contains and how it is meant to be used is ordinary. A medical guarantee is not.
Check the potency math
Total milligrams versus milligrams per serving
The number printed largest on the front of a package is usually the total CBD in the whole container, which on its own tells you nothing about a single dose. Three figures matter, and labels do not always make all three easy to find: total CBD in the container, CBD per serving, and the number of servings. Divide the first by the last and you have your actual dose. When one of the three is missing, ask why before you buy.
Cost per milligram beats sticker price
Sticker price tells you very little, because two bottles of the same size can hold very different amounts of CBD. Divide the price by the total milligrams instead and you get a figure you can compare across a whole shelf. The cheaper bottle is not reliably the cheaper product. Ask whether the formula is full spectrum, broad spectrum, or isolate as well, since trace THC in a full spectrum product matters if you face workplace drug testing.
Check for interactions before you start
The question is not overcautious
CBD is processed by the same family of liver enzymes that metabolize a long list of prescription drugs, so it can push blood levels of those medications up or down. Anyone taking blood thinners, seizure medication, or immunosuppressants has a concrete reason to check first.
Ask someone qualified
A pharmacist or physician can review your actual list of medications. Retail staff can explain what a product contains and how it is meant to be used, and a good one will tell you when a question belongs with a clinician instead. Federal guidance also advises against cannabis in any form during pregnancy and while breastfeeding.
What this adds up to
The category did not get worse over the past five years. It got sorted. Products that never should have been sold next to the lottery tickets moved to retailers who answer to a regulator, and the ones that stayed put are easier to evaluate than they used to be.
Four checks cover almost all of it: an independent lab report tied to your batch, a label that stays inside its lane, honest arithmetic on potency, and a straight answer about interactions. None of that takes long. The reaction you get is often as informative as the reply.
This content is provided for informational purposes only and is not a substitute for professional advice. AFP editorial staff were not involved in the creation of this content.
Support AFP
Share
